# Vitamin B12: a Biological Marker of Systemic Disease or Infection Flare-up in Patients Treated with Tocilizumab?

> **NCT06654154** · NA · RECRUITING · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 56 (estimated)

## Conditions studied

- Level of Serum Vitamin B12 Level (in Pmol/L) If Relapse of (AI/ID) Under Tocilizumab
- Level of Serum Vitamin B12 Level (in Pmol/L) If Infection Under Tocilizumab

## Interventions

- **DIAGNOSTIC_TEST:** variation of serum level vitamine B12

## Key facts

- **NCT ID:** NCT06654154
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-03
- **Primary completion:** 2026-03
- **Final completion:** 2029-03
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06654154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06654154, "Vitamin B12: a Biological Marker of Systemic Disease or Infection Flare-up in Patients Treated with Tocilizumab?". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06654154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*